ACTallo: An Engineered T-Cell Therapy Platform for Adoptive Cell Therapies
Time: 2:00 pm
day: Post-Conference Solid Tumor Focus Day
Details:
- Immatics develops TCR-based cancer immunotherapies by combining the discovery of naturally HLA-presented targets with the discovery of the right T-cell receptors
- T-cell receptor (TCR)-based immunotherapies hold a great potential for the treatment of solid tumors by targeting extra- and intracellular tumor-associated antigens
- For our allogeneic ACT platform, we employ CRISPR/Cas technology to introduce 1) targeted killing capacities by expressing a highly functional TCR or CAR, 2) cloaking technology to avoid fast graft rejection, 3) armoring to counteract the suppressive tumor microenvironment
